Renal Cell Carcinoma

About Renal Cell Carcinoma Clinical Trials (Click to Open)

Join Clinical Trials for Renal Cell Carcinoma (Kidney Cancer)

Renal Cell Carcinoma

General Purpose:

Kidney cancer refers to three specific types of cancer: renal cell carcinoma, renal pelvis carcinoma, and Wilms tumor. Renal cell carcinoma develops in the lining and small tubes of the kidneys, whereas renal pelvis carcinoma develops in the center of the kidneys, where urine collects before it is transferred to the bladder.

Wilms tumor typically develops in children under five years of age. It is estimated that in 2012, over 64,000 new cases of kidney cancer will be diagnosed in adults, and over 13,000 will die. Current research regarding kidney cancer seeks to identify its causes and ways in which to prevent its development.

In addition, treatments are being refined in order to improve the survival rate of kidney cancer, and research is also being conducted to better understand the genetic changes that cause kidney cells to become cancerous.  A major thrust of kidney cancer research is to try and identify specific factors about an individual’s kidney cancer that might make that tumor more likely to respond to a particular medicine.  

What Will Renal Cell Carcinoma Clinical Trials Be Like?

Clinical trials for renal cell carcinoma (kidney cancer) may involve many common tests and procedures; however, the ultimate design of the particular study will determine which specific procedures you will undergo. Examples of specific tests and procedures that mayRenal Cell Carcinoma be used in a clinical trial for kidney cancer include the following:

  • Physical exam
  • Blood and/or tissue sample for the purposes of conducting genetic testing.
  • If the study is evaluating a new type of medication or vaccine, blood and/or urine tests may be performed to monitor how your body metabolizes the medication or how effectively your body has responded to the vaccine.
  • Urine tests to detect the presence of blood cells.
  • Biopsy
  • Imaging procedures such as computed tomography (CT scan, or “CAT scan”) or magnetic resonance imaging (MRI) scans. These imaging procedures are non-invasive and provide detailed pictures of areas inside your body. Conventional x-rays may also be used.
  • Surgery
  • Ultrasound
  • Determination and monitoring of the Fuhrman grade. Kidney cancers are typically graded on a scale of one to four; the lower the number, the better the prognosis.
  • Quality of life assessments to evaluate how your cancer is impacting your ability to perform activities of daily living.
  • Pain assessments
  • Dietary assessments

Typical Renal Cell Carcinoma Clinical Trial Protocol:

Research related to kidney cancer is investigating a number of aspects pertaining to the prevention, diagnosis, and treatment of kidney cancer. Examples of sample clinical trials include the following:

  • A clinical trial that evaluates the effectiveness of using a therapy that has been carefully selected to match individual patient and tumor characteristics (i.e., “targeted therapy”)
  • A clinical trial that investigates a new drug that blocks specific activities within cells that are known to cause them to become cancerous.
  • A clinical trial that compares the use of high-intensity focused ultrasound versus standard radiation therapy techniques to kill kidney cancer cells.
  • A clinical trial that compares targeted therapy plus standard chemotherapy to standard chemotherapy alone for the treatment of advanced kidney cancer.
  • A study designed to treat kidney cancer through the use of vaccines designed to boost the body’s immune response to kidney cancer cells.

A brief word about randomized trials and placebos:

Many clinical trials involve the comparison of an investigational treatment to a “standard” Renal Cell Carcinomatreatment. Some studies determine which therapy a patient receives through a process known as randomization, in which patients are randomly assigned to receive either the investigational treatment or the standard treatment.

On occasion, a trial will investigate the use of a standard treatment plus a new drug compared to standard treatment plus a placebo. Placebos are inactive or “sham” treatments that are identical in appearance to the active treatment but have no therapeutic value.

Placebos are necessary to help determine if adverse effects that occur during the clinical trial are the result of the investigational treatment or due to some other factor. They also allow researchers to measure the effects of the active treatment and observe what would have happened without it.

In rare instances where no standard therapy exists, or when a new drug is being evaluated for the first time in a specific cancer, the investigational treatment might be compared to a placebo alone. In these types of trials, those patients who are randomized to the placebo group do not receive an active treatment.

This is rarely done in cancer clinical trials; however it may occasionally be necessary from a scientific standpoint. Placebo-only trials will only be done when ethically appropriate and when patients have been adequately informed that they may end up receiving the placebo rather than the active treatment.

It is very important to note, however, that no one should ever participate in such a placebo trial when there is a widely available and highly effective standard treatment already in existence for their particular type of cancer and clinical situation.

Trial Eligibility and Medical Information Needed:

The type of clinical trial you may be eligible for often depends on many factors, including your disease stage, treatment history, and a variety of clinical findings. Therefore, it is Renal Cell Carcinomaimportant to know many details pertaining to your specific diagnosis when searching for clinical trials. Examples of the details you will want to have on hand include:

  • The name, location, size, stage, and cell type of your cancer, as well as the locations of any metastases you have. Also know these details for any prior cancer you have had.
  • Know your performance status, which estimates how well you perform normal activities of daily living. Examples: Karnofsky Performance Scale (KPS) and the ECOG scale.
  • Know your treatment history, including chemotherapy, radiation therapy, immunotherapy, and/or surgery.
  • Know your blood cell counts, liver function test results, and kidney function test results.

Suggested Search Terms:

Remember that “kidney cancer” refers collectively to three specific types of kidney tumors; therefore, you may find it easier to refine your search by using the name of your specific kidney tumor (i.e., renal pelvis carcinoma, Wilms tumor, etc.).

If doing so narrows your search findings too drastically, try a more general search using the phrase “kidney cancer.” Regardless of which type of kidney cancer you have, or if you are using the broad term “kidney cancer,” adding the following terms to your query may provide useful findings: “prevention,” “treatment,” “surgery,” “chemotherapy,” “radiation therapy,” “treatment side effects,” “hereditary,” “genetics,” “children,” “pediatric,” “advanced,” “pain,” and “metastatic.”

Current Search Term:

“Renal Cell Carcinoma”

Add Comments or Questions

Intermittent Nivolumab in Metastatic Renal Cell Carcinoma Patients

Condition:   Metastatic Renal Cell Carcinoma
Intervention:   Drug: Nivolumab
Sponsor:   Case Comprehensive Cancer Center
Not yet recruiting - verified April 2017

Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Intervention:   Drug: TAK-228
Sponsors:   Dana-Farber Cancer Institute;   Millennium Pharmaceuticals, Inc.
Not yet recruiting - verified April 2017

Study to Evaluate Safety, Pharmacokinetics and Therapeutic Activity of RO6874281 as a Combination Therapy in Participants With Unresectable Advanced and/or Metastatic Renal Cell Carcinoma (RCC)

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Obinutuzumab;   Drug: Atezolizumab;   Drug: Bevacizumab;   Drug: RO6874281
Sponsor:   Hoffmann-La Roche
Recruiting - verified May 2017

Ablative tReatment of Inoperable REnal Cell Carcinoma Using STereotactic Body Radiotherapy (ARREST-study)

Condition:   Renal Cell Carcinoma
Intervention:   Radiation: ARREST-study
Sponsor:   UMC Utrecht
Recruiting - verified July 2016

Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment

Condition:   Metastatic Renal Cell Carcinoma
Sponsors:   Pfizer;   TFS Trial Form Support
Recruiting - verified May 2017

Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan

Condition:   Renal Cell Carcinoma
Sponsor:   Pfizer
Active, not recruiting - verified April 2017

A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Drug: AGS-16C3F;   Drug: Axitinib
Sponsor:   Agensys, Inc.
Recruiting - verified May 2017

A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population

Condition:   Renal Cell Carcinoma
Intervention:   Drug: Sunitinib malate
Sponsor:   vghtpe user
Enrolling by invitation - verified June 2016

Exploratory Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Drug: Pazopanib;   Drug: Sorafenib;   Drug: Radium-223
Sponsors:   Dana-Farber Cancer Institute;   Bayer
Active, not recruiting - verified January 2017

Post Marketing Surveillance for PROSENSE™ a Cryotherapy Treatment of Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Intervention:   Device: PROSENSE™
Sponsors:   IceCure Medical Ltd.;   Bnai Zion Medical Center
Recruiting - verified February 2017

Comparison of Microwave Ablation-Assisted Enucleation and Conventional Laparoscopic Partial Nephrectomy in the Treatment of T1a Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Interventions:   Procedure: laparoscopic microwave ablation-assisted enucleation;   Procedure: conventional laparoscopic partial nephrectomy
Sponsors:   RenJi Hospital;   National Natural Science Foundation of China
Completed - verified April 2017

A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Intervention:   Device: CyberKnife
Sponsor:   Beth Israel Deaconess Medical Center
Recruiting - verified April 2017

A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Intervention:   Drug: TRC105 and Axitinib
Sponsor:   Tracon Pharmaceuticals Inc.
Recruiting - verified November 2016

Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Intervention:   Other: No intervention
Sponsor:   Bayer
Completed - verified October 2016

Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases

Condition:   Metastatic Renal Cell Carcinoma
Intervention:   Drug: sorafenib
Sponsor:   Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Recruiting - verified March 2017

Neoadjuvant Pazopanib in Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Intervention:   Drug: Pazopanib
Sponsors:   UNC Lineberger Comprehensive Cancer Center;   GlaxoSmithKline
Completed - verified March 2017

Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Intervention:   Drug: BKM-120 Bevacizumab
Sponsors:   Toni Choueiri, MD;   Beth Israel Deaconess Medical Center
Completed - verified September 2016

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.

Condition:   Renal Cell Carcinoma
Intervention:   Drug: RAD001
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified February 2017

Study of Hydroxychloroquine Before Surgery in Patients With Primary Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Intervention:   Drug: Hydroxychloroquine (HC)
Sponsors:   University of Pittsburgh;   National Institutes of Health (NIH)
Terminated - verified October 2016

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Condition:   Metastatic Renal Cell Carcinoma
Interventions:   Drug: Lenvatinib;   Drug: Everolimus
Sponsor:   Eisai Inc.
Active, not recruiting - verified August 2016

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Everolimus;   Drug: BNC105P
Sponsors:   Hoosier Cancer Research Network;   Bionomics Limited
Completed - verified April 2017

Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Sunitinib;   Procedure: Nephrectomy
Sponsors:   M.D. Anderson Cancer Center;   Pfizer
Active, not recruiting - verified September 2016

A Phase I/II Study to Assess the Safety and Efficacy of Vaccinations With Allogeneic Dendritic Cells: Autologous Tumor-Derived Cells Subjected to Electrofusions in Patients With AJCC Stage IV Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Intervention:   Biological: Electrofusion DC vaccine
Sponsors:   Beth Israel Deaconess Medical Center;   Genzyme, a Sanofi Company
Completed - verified March 2017

Tumor Registry of Advanced Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Sponsors:   iOMEDICO AG;   Arbeitskreis Klinische Studien;   Bund der Urologen e.G.
Recruiting - verified February 2017

Cediranib (AZD2171, RECENTIN™) in Metastatic or Recurrent Renal Cell Carcinoma

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Cediranib;   Drug: Cediranib Placebo
Sponsor:   AstraZeneca
Completed - verified November 2016

Refine Your Search Advanced Search